About us

Warehouse worker in the Abacus Medicine warehouse in the Netherlands

The Abacus Medicine Group is built on a strong purpose. We are highly conscious of our contribution to society. This has been the case ever since the family business was founded by father and son in 2004.

Today, the Abacus Medicine Group is a large and growing entity,  where diversity is treasured. We work as a team, and our commercial activities provide jobs, careers, and livelihoods for hundreds of people in dozens of countries.

As the Abacus Medicine Group grows, so does our societal impact. We recognize our obligation to our stakeholders and to the wider society. This is reflected in our Sustainability programs.

We are innovative, dedicated, and we care. We improve global healthcare through better access to medicine.​

In the Abacus Medicine Group, we are proud to serve a purpose beyond ourselves.

When we compete in the market, we improve availability and reduce prices of life-critical medicines, so they become more widely available. Our core parallel distribution business helps us achieve exactly that. And with our pharma service business, Abacus Medicine Pharma Services, and our Dutch pharmaceutical wholesaler, Pluripharm, we provide better access to pharmaceutical products for even more patients, doctors
and pharmaceutical manufacturers.

The Abacus Medicine Group has grown fast since the beginning, and as we grow, we are able to make an ever-increasing contribution. To us, this is the hallmark of a sustainable business model.

Innovative
We believe anything is possible. We encourage original ideas. We are flexible and always ready to change plans if an opportunity arrives.

Dedicated
We are intensely focused on our tasks. We are relentless and willing to go that extra mile.

We care
We respect and value our fellow human beings: Internal colleagues, external business partners and the societies, we are part of. We do not act only in our own interest, but are conscious of others and believe in mutual, long-term partnerships.

Global
Today, our core business is in Europe. Tomorrow, we will be a global company. This is just as much about mindset, as it is about time zones and language versions. We must think and act globally.

Access
What we do, is all about access. We provide access to medicine in countries, where patients might not have it otherwise. We provide access for companies conducting clinical trials. When we make medicine more affordable through parallel trade, we also make it more accessible.

We strive to uphold these values, both to society and to our external and internal relations. Therefore, we have created our own compliance framework.

Management & Board of Directors

The Abacus Medicine Group is headed by our Board of Directors and the Executive Management team. 

Sustainability

We want to do better, where it really matters.

Sustainability in the Abacus Medicine Group is an ongoing and never-ending process. From year to year, gradual changes in our business landscape and in the priorities of our stakeholders will affect our Sustainability priorities.

In 2022, we have defined six Focus Programs focused around our production activities as well as our community engagement and diversity management. This year, we will have a high focus on our waste handling in all aspects.

ESG Reporting
The program will seek to include more ESG metrics and potentially adjust some the already introduced metrics.

Transport
The program will continue its focus from previous years by continuing to investigate ways to optimize our environmental impact relating to transportation activities.

Waste & Sourcing
This new program will have a holistic view on our production process from start to finish across our various production sites.

Supplier Code of Conduct
The program will seek to enforce the Supplier Code of Conduct will all external suppliers while codifying processes internally.

Diversity & Inclusion
The program will seek to broaden its scope globally across the whole Abacus Medicine Group with the aim of launching a global Diversity & Inclusion strategy.

Community Engagement
The program will continue to raise awareness internally and externally about our sustainability activities through stories and relevant events.

Little boy holding young tree

Supplier Code of Conduct
The program will seek to enforce the Supplier Code of Conduct will all external suppliers while codifying processes internally.

Diversity & Inclusion
The program will seek to broaden its scope globally across the whole Abacus Medicine Group with the aim of launching a global Diversity & Inclusion strategy.

Community Engagement
The program will continue to raise awareness internally and externally about our sustainability activities through stories and relevant events.

Sustainability Report 2021

Employees, environment and more. How did we progress and what are our plans?

Sustainability Policy

Sustainability in the Abacus Medicine Group is rooted in the UN Sustainable Development Goals.

Timeline

The Abacus Medicine Group is a young group of companies that has come far in a short time.
Browse through the main events of our journey below.

Abacus Medicine is founded by father and son: John and Flemming Wagner

2004

First deliveries to Danish pharmacies and hospitals

2006

Abacus Medicine becomes the largest parallel importer of medicine to the Danish hospital network

2009

Beyond borders: Sweden becomes our first export market

2010

Abacus Medicine Hungary is established and we have our first deliveries to Germany

2012

First deliveries in the Netherlands

2014

First deliveries in the UK and in Austria

2015

Turnover exceeds 1 billion DKK

2016

First deliveries in France and Finland and the acquisition of Aposave (now Abacus Medicine Pharma Services)

2017

Production begins at new, second site in Alkmaar in the Netherlands

2018

Chr. Augustinus Fabrikker joins as strategic investor

2019

Acquisition of Pluripharm and we reach 1,000 employees

2020

Whisteblower Scheme

The Abacus Medicine Group has established a Whistleblowing Scheme in order to allow the reporting of potential violations of the law and serious violations of internal company policy and procedures.